Challenges in the treatment of patients with essential thrombocythemia and acute coronary syndrome
- 119 Downloads
Essential thrombocythemia (ET) is an acquired clonal hematological stem-cell disorder that is characterized by a persistent increase in platelet count over 600,000/μl and elevated megakaryocyte levels in the bone marrow. Patients with ET are on the one hand at risk of thrombosis and on the other hand of hemorrhagic events especially in patients with very high platelet accounts. We report two illustrative cases with ET and acute coronary syndrome from our recent clinical experience illustrating the challenges in the antithrombotic treatment of these patients.
KeywordsEssential thrombocythemia Thrombosis Acute coronary syndrome Cytoreductive treatment Antiplatelet therapy
- 18.Harrison CN, Campbell PJ, Buck G Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR (2005) United Kingdom medical research council primary thrombocythemia 1 study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353(1):33–45PubMedCrossRefGoogle Scholar